Identification of atopic dermatitis subgroups in children from two longitudinal birth cohorts by Paternoster, Lavinia et al.
                                                              
University of Dundee
Identification of atopic dermatitis subgroups in children from two longitudinal birth
cohorts
Paternoster, Lavinia; Savenije, Olga E. M.; Heron, Jon; Evans, David M.; Vonk, Judith M.;
Brunekreef, Bert; Wijga, Alet H.; Henderson, A. John; Koppelman, Gerard H.; Brown, Sara J.
Published in:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2017.09.044
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Paternoster, L., Savenije, O. E. M., Heron, J., Evans, D. M., Vonk, J. M., Brunekreef, B., ... Brown, S. J. (2017).
Identification of atopic dermatitis subgroups in children from two longitudinal birth cohorts. Journal of Allergy and
Clinical Immunology. https://doi.org/10.1016/j.jaci.2017.09.044
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Accepted Manuscript
Identification of atopic dermatitis subgroups in children from two longitudinal birth
cohorts
Lavinia Paternoster, PhD, Olga E.M. Savenije, MD PhD, Jon Heron, PhD, David M.
Evans, PhD, Judith M. Vonk, PhD, Bert Brunekreef, PhD, Alet H. Wijga, PhD, A. John
Henderson, MD, Gerard H. Koppelman, MD PhD, Sara J. Brown, MD FRCPE
PII: S0091-6749(17)31739-6
DOI: 10.1016/j.jaci.2017.09.044
Reference: YMAI 13102
To appear in: Journal of Allergy and Clinical Immunology
Received Date: 11 June 2017
Revised Date: 7 August 2017
Accepted Date: 20 September 2017
Please cite this article as: Paternoster L, Savenije OEM, Heron J, Evans DM, Vonk JM, Brunekreef
B, Wijga AH, Henderson AJ, Koppelman GH, Brown SJ, Identification of atopic dermatitis subgroups
in children from two longitudinal birth cohorts, Journal of Allergy and Clinical Immunology (2017), doi:
10.1016/j.jaci.2017.09.044.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Identification of atopic dermatitis subgroups in children from two longitudinal birth cohorts 1 
Lavinia Paternoster PhD
1
, Olga E.M. Savenije MD PhD 
2,3
, Jon Heron PhD
4
, David M. Evans PhD
1,5
, 2 
Judith M. Vonk PhD
3,6
, Bert Brunekreef PhD
7,8
, Alet H. Wijga PhD
9
, A. John Henderson MD
4
, Gerard H. 3 
Koppelman MD PhD
2,3
* and Sara J. Brown MD FRCPE
10,11
*. 4 
*Joint last authors 5 
1. MRC Integrative Epidemiology Unit, School of Social & Community Medicine, University of 6 
Bristol, Bristol, UK 7 
2. University of Groningen, University Medical Center Groningen, Department of Paediatric 8 
Pulmonology and Paediatric Allergology, Beatrix Children’s Hospital, Groningen, The Netherlands 9 
3. University of Groningen, University Medical Center Groningen, Groningen Research Institute for 10 
Asthma and COPD (GRIAC), Groningen, The Netherlands 11 
4. School of Social & Community Medicine, University of Bristol, Bristol, UK 12 
5. The University of Queensland Diamantina Institute, Translational Research Institute, Princess 13 
Alexandra Hospital, Brisbane 4102, Australia 14 
6. University of Groningen, University Medical Center Groningen, Department of Epidemiology, 15 
Groningen, The Netherlands 16 
7. Utrecht University, Institute for Risk Assessment Sciences, Utrecht, The Netherlands 17 
8. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 18 
The Netherlands 19 
9. National Institute for Public Health and the Environment, Center for Nutrition, Prevention and 20 
health Services, Bilthoven, The Netherlands 21 
10. Skin Research Group, School of Medicine, University of Dundee, Dundee, DD1 9SY Scotland, UK 22 
11. Department of Dermatology, Ninewells Hospital, Dundee, DD1 9SY Scotland, UK 23 
 24 
Corresponding author: 25 
Dr Lavinia Paternoster 26 
MRC Integrative Epidemiology Unit at the University of Bristol 27 
Bristol Medical School 28 
Oakfield House, Oakfield Grove, 29 
Bristol, UK, BS8 2BN 30 
l.paternoster@bristol.ac.uk 31 
 32 
Funding: 33 
This work and LP were supported by a UK Medical Research Council Fellowship (MR/J012165/1). LP 34 
& DME work in the Medical Research Council Integrative Epidemiology Unit at the University of 35 
Bristol which is supported by the Medical Research Council and the University of Bristol 36 
(MC_UU_12013/4). DME is supported by an Australian Research Council Future Fellowship 37 
(FT130101709).  SJB holds a Wellcome Trust Senior Research Fellowship in Clinical Science 38 
(106865/Z/15/Z). The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and 39 
the University of Bristol provide core support for ALSPAC. The PIAMA birth cohort was funded by the 40 
Netherlands Organization for Health Research and Development, the Netherlands Organization for 41 
Scientific Research, the Lung Function of the Netherlands, the Netherlands Ministry of Spatial 42 
Planning, Housing, and the Environment, and the Netherlands Ministry of Health, Welfare, and 43 
Sport.44 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract 45 
Background: Atopic dermatitis (AD) is a prevalent disease with variable natural history. Longitudinal 46 
birth cohort studies provide an opportunity to define subgroups based on disease trajectories, which 47 
may represent different genetic and environmental pathomechanisms.  48 
Objective: To investigate the existence of distinct longitudinal phenotypes of AD and test whether 49 
these findings are reproducible in two independent cohorts.  50 
Methods: The presence of AD was examined in two birth cohort studies including 9,894 children 51 
from the UK (ALSPAC) and 3,652 from the Netherlands (PIAMA). AD was defined by parental report 52 
of a typical itchy and/or flexural rash. Longitudinal latent class analysis was used to investigate 53 
patterns of AD from birth to the age of 11 to 16 years. We investigated associations with known AD 54 
risk factors, including FLG null mutations, 23 other established AD-genetic risk variants and atopic 55 
comorbidity.  56 
Results: Six latent classes were identified, representing subphenotypes of AD, with remarkable 57 
consistency between the two cohorts. The most prevalent class was early-onset-early-resolving AD, 58 
which was associated with male gender. Two classes of persistent disease were identified (early-59 
onset-persistent and early-onset-late-resolving); these were most strongly associated with the AD-60 
genetic risk score as well as personal and parental history of atopic disease. A yet unrecognised class 61 
of mid-onset-resolving AD, not associated with FLG mutations, but strongly associated with asthma, 62 
was identified. 63 
Conclusion: Six classes based on temporal trajectories of rash were consistently identified in two 64 
population-based cohorts. The differing risk factor profiles and diverse prognoses demonstrate the 65 
potential importance of a stratified medicine approach for AD. 66 
 67 
Clinical Implications 68 
Atopic dermatitis ranges from a transient condition to lifelong morbidity. This study has identified 69 
distinct subphenotypes of atopic dermatitis in children, which could indicate the importance of a 70 
stratified approach to management of this complex disease.    71 
 72 
Capsule Summary 73 
Longitudinal latent class analysis models the course of disease subsets over time. Atopic dermatitis 74 
in childhood shows diversity in risk factors, prognoses and comorbidities. This study demonstrates 75 
robust subphenotypes of AD in two population cohorts.      76 
  77 
 78 
 79 
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AD  atopic dermatitis 92 
ALPSAC  Avon Longitudinal Study of Parents and Children 93 
BIC  Bayesian information criterion 94 
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LLCA  longitudinal latent class analysis 96 
PIAMA  Prevention and Incidence of Asthma and Mite Allergy 97 
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Introduction 99 
In clinical practice atopic dermatitis (AD; eczema) demonstrates a characteristic itchy erythematous 100 
rash
1
 but it has a heterogeneous presentation with variations in timing of onset, persistence
2,3
, 101 
distribution, severity, association with allergic sensitisation
4
 and comorbidity with other atopic 102 
diseases
5,6
. Whilst the classification of eczema cases into atopic and non-atopic forms is 103 
commonplace (in part because the underlying aetiology of these may be different
4
), the 104 
heterogeneity of longitudinal disease course in AD is less well studied. The majority of AD cases are 105 
diagnosed in early childhood and whilst most resolve during childhood, some persist into adulthood. 106 
We hypothesised that divergent temporal disease patterns may be caused by different genetic and 107 
environmental aetiological mechanisms. Understanding these differences could influence how AD is 108 
defined and treated, paving the way for a phenotype-driven, more personalised approach to the 109 
management of childhood AD.  110 
AD is a strongly heritable condition. A total of 31 risk loci have been identified in genetic association 111 
studies, including 24 loci that were discovered in white European populations
7-13
. The cardinal 112 
feature of an itchy erythematous rash is central to all case definitions for AD, but large genetic 113 
studies have used a broad case definition, including self-reported AD over a wide age range of 114 
paediatric and adult patients. This broad case definition has been necessary to allow collection of 115 
the large numbers of cases required for genome-wide analyses, but it does not allow for detailed 116 
sub-stratification of AD and dictates that such studies are powered to detect variants common 117 
across subtypes of disease, whilst potentially missing variants with more specific effects on subtypes 118 
of the disease. 119 
The aim of our study was to investigate the existence of longitudinal subphenotypes of AD and to 120 
test whether these findings are reproducible in two independent birth cohorts. We used longitudinal 121 
latent class analysis (LLCA), a statistical technique which can be used to model potential subgroups 122 
within a dataset to identify different longitudinal patterns of disease. We applied LLCA to cohorts 123 
from the United Kingdom and the Netherlands from birth to 16 years or 12 years, respectively. We 124 
tested each latent class for association with known genetic and non-genetic risk factors for AD and 125 
atopic comorbidities, to investigate the existence of distinct subgroups of disease having different 126 
aetiological and prognostic profiles.  127 
 128 
  129 
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Methods 130 
ALSPAC: Avon Longitudinal Study of Parents and Children 131 
ALSPAC is a longitudinal population-based birth cohort study of 14,701 children from Avon, UK. The 132 
study protocol has been described previously
14
 and further details are in the Online Repository. 133 
Information regarding the presence/absence of rash consistent with AD were extracted from 134 
questionnaires completed by the mothers when the children were aged between 6 months and 16.5 135 
years (at 6, 18, 30, 42, 57, 69, 81, 103, 128, 140, 166 and 198 months). At each timepoint AD was 136 
defined as a positive response to one of the following questions: “Has your child had an itchy, dry, 137 
oozing or crusted rash on the face, forearms or shins?” (at 6 months of age); “Has your child had a 138 
skin rash in the joints and creases of their body (e.g. behind the knees, elbows, under the arms) in the 139 
past 6-12 months?” (18-166 months); “Has your child had an itchy rash which was coming and going 140 
for at least 6 months in the past 12 months and confined to the creases of the knees/ankles/elbows 141 
or wrists?” (at 16 years). 142 
Non-genetic risk factors were selected based on existing evidence for association with AD
15
 and data 143 
availability in the two cohorts. Parental history of AD and asthma were parent-reported in 144 
questionnaires completed by the parents or guardians. Breast feeding was coded as a binary variable 145 
of never versus any breast feeding as reported by the mother when the child was 15 months old. Cat 146 
exposure was coded as a binary variable of 0 or 1+ cats in the home, as reported by the mother at 8 147 
weeks’ gestation. Children were classified as asthmatic at 7 and 13 years if a parent answered ‘yes’ 148 
to ‘Has your child had asthma in the past 12 months?’. Total immunoglobulin E (IgE) was measured 149 
in venous blood at 7 years and total IgE>75kU/L was defined as elevated. 150 
 151 
DNA was obtained from blood and genotypes were determined according to methods described in 152 
the Online Repository. Individuals were categorised into two groups: those with and those without 153 
any of the 4 FLG null mutations tested (i.e. FLG
-/- 
and FLG
+/-
versus FLG
+/+
)
16
. Genotypes for the 154 
remaining 23 established (and replicated) European AD risk variants
13
 were combined into a score, 155 
with the value representing a sum of the risk alleles carried across the 23 variants. 156 
 157 
PIAMA: Prevention and Incidence of Asthma and Mite Allergy 158 
PIAMA is a Dutch multicenter birth cohort of 3963 children from allergic and non-allergic mothers. 159 
The study protocol has been described previously
17
 and further details are in the Online Repository.  160 
The International Study of Asthma and Allergies in Childhood–based questionnaires were used to 161 
report symptoms of AD between 3 months and 11 years of age (3, 12, 24, 36, 48, 60, 72, 84, 96, 132 162 
months). At each timepoint AD was defined as a positive response to both of the following two 163 
questions: “Has your child had an itching rash that was variably present in the last 12 months?” (or 164 
ever at 3 and 12 months) and, “Was this rash present around the eyes/ears, foreside ankles, inner 165 
side knees or inner side elbows?” (also neck at 3 and 12 months). 166 
Parental history of asthma was taken from questionnaires which asked “Have you ever had 167 
asthma?” Any versus never breast feeding was assessed by questions on infant feeding in the 168 
questionnaires administered at 3 months and at 1 year of age. Cat exposure was coded as a binary 169 
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variable of 0 or 1+ cats in the home at 3 months after birth. Asthma at 7 and 11 years was defined as 170 
a parental report of a doctor’s diagnosis of asthma at any time and a parental report of asthma in 171 
the last 12 months at age 7 and 11. Total IgE was measured in venous blood at age 8 years and 172 
>75kU/L was defined as elevated.  173 
 174 
DNA was obtained from blood and mouth swabs and genotypes were determined according to 175 
methods described in the Online Repository. FLG genotype categorisation and the non-FLG genetic 176 
risk score were constructed, as for ALSPAC. 177 
 178 
Statistical analysis 179 
Longitudinal latent class analysis (LLCA) was used to investigate heterogeneity in patterns of AD. As 180 
the name suggests, this method is applied in longitudinal settings
18,19
, where the aim is to identify 181 
distinct subgroups in longitudinal multivariate categorical data. This is akin to cluster analysis, but is 182 
more appropriate for binary data and allows for assignment based on probability, rather than 183 
definitive partitioning of individuals into classes. Starting with a single latent class, additional classes 184 
are added until measures that estimate model fit are optimised. Several statistical criteria (including 185 
low Bayesian Information Criterion (BIC), Vuong-Lo-Mendell-Rubin likelihood ratio test and entropy) 186 
were assessed to determine the optimal number of classes; full details are given in the Online 187 
Repository. Model fitting was carried out in Mplus version 7.0
20
. 188 
 189 
Model fit was primarily assessed using only those individuals for whom there was no missing AD 190 
symptom data. However, to optimise the use of available data and maximise the cohort size, results 191 
were compared to analyses which included individuals for whom data were available for ≥50% of the 192 
time points studied (≥6 of the 12 time-points in ALSPAC and ≥5 of the 10 time points in the PIAMA 193 
cohort). Association analyses primarily focused on this larger (although incomplete) dataset, but 194 
results were compared with models from the smaller but more complete dataset. 195 
 196 
Associations of risk factors and comorbidities with the latent classes were tested using a manual 197 
implementation of the bias-adjusted three step analysis
21
. This method accounts for uncertainty in 198 
class assignment (see Online Repository). Associations with established risk factors (sex; family 199 
history of atopy; breastfeeding; presence of pet cat in the household; FLG loss-of function mutation; 200 
genetic risk score of 23 established white European AD variants) were tested using multinomial 201 
regression, whilst atopic comorbidities (asthma at ages 7 and 11 or 13 years; elevated IgE at age 7 or 202 
8 years) were tested using logistic regression. 203 
 204 
  205 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Results 206 
LLCA in the ALSPAC cohort 207 
The prevalence of AD in ALSPAC declined over time (Fig 1a) from 27% in the first year of life to 7% at 208 
16.5 years of age. Data were available from all 12 time points for a total of 3,480 individuals. The 6-209 
class model was considered the best fit to the data (as defined by the lowest Bayesian information 210 
criterion), however only small improvements were seen between the 4-class and the 6-class models 211 
(Table E1 & Fig E1, Online Repository). We present the results of the 6-class model as the primary 212 
analysis, but show the results for the simpler 4-class model in the Online Repository, which for most 213 
analyses produced very similar results. 214 
9,894 individuals had data available from at least 6 of the 12 time points and the model fit 215 
parameters were broadly consistent with the smaller but more complete dataset (Table E1, Online 216 
Repository). Comparison of models from the larger incomplete and smaller but complete datasets 217 
showed that the prevalence patterns of AD by class were very similar (Table E3, Online Repository) 218 
and only 3% of children (116/3480) changed best-fit class between the 6-class models in each 219 
analysis (Table E2, Online Repository).  220 
Fig 2a shows the estimated prevalence of a rash characteristic of AD at each time-point across the 6 221 
classes in the analysis of 9,894 individuals. Descriptions of the classes alongside the labels we gave 222 
each class are given in Table I. 223 
The estimated prevalence of a rash characteristic of AD at each time point for the 4-class model are 224 
displayed in Fig E3 (Online Repository). The 4 classes can be described as: Unaffected individual or 225 
transient AD (61.9%); early-onset-persistent AD (10.7%); early-onset AD resolving by 11 years of age 226 
(16.5%); later-onset AD after 3.5 years of age (10.9%). These 4 classes show substantial overlap with 227 
the 6-class assignment (Table E4, Online Repository). 228 
LLCA in the PIAMA cohort 229 
The prevalence of AD in PIAMA declined only slightly from 18% in the first year of life to 14% by 11 230 
years of age (Fig 1b). Data were available from all 10 time points for 2,063 individuals. 3,652 231 
individuals had data available from at least 5 of these time points, and we present the results from 232 
the analysis of this larger incomplete dataset. LLCA model fit was similar to ALSPAC, with lowest BICs 233 
achieved between the 4-class and 6-class models (Table E5, Fig E2, Online Repository), the resulting 234 
class patterns following a remarkably similar pattern to ALSPAC (Fig 2b, Fig E4, Online Repository), 235 
with comparable class prevalences (Table I, Fig1b). 236 
As for ALSPAC, we present association results for the 6-class model as the primary analysis because 237 
this showed best fit. Comparison of assignment between 4- and 6-class models is shown in Table E7 238 
(Online Repository) and association results from the 4-class model are also shown in the Online 239 
Repository. 240 
Associations between latent classes with family history and selected environmental risk factors 241 
The associations of 6 classes with potential AD risk factors are summarised in Table II. The results 242 
from the smaller but complete dataset and the 4-class models are shown in Tables E9 & E10 (Online 243 
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Repository). Similar conclusions could be drawn from these models, unless otherwise specified. 244 
In ALSPAC, taking the ‘unaffected or transient AD’ class as the baseline category, being female was a 245 
risk factor for the early-onset-persistent, mid-onset and late-onset classes, the strongest association 246 
being with the late-onset class (OR=1.90 (95% confidence interval 1.48-2.44) p=4x10
-7
). However, 247 
male gender was a risk factor for the early-onset-early-resolving class (OR=1.33 (95% CI 1.10-1.61) 248 
p=0.004). A similar pattern was observed in PIAMA, where the strongest association with female 249 
gender was observed with the late-onset group (OR=1.87 (95% CI 1.21-2.90) p=0.005) and there was 250 
evidence of an association between male gender and early-onset-early-resolving class. 251 
Maternal history of AD was associated with all classes in ALSPAC, with the strongest association in 252 
the persistent class (OR=3.16 (95% CI 2.60-3.83) p=4x10
-31
). A similar pattern (albeit with weaker 253 
evidence for all classes) was observed in ALSPAC for maternal history of asthma, where again the 254 
strongest association was with the persistent class (OR=1.54 (95% CI 1.22-1.95) p=3x10
-4
). Paternal 255 
history of asthma showed a similar association with this class (OR=1.59), but the smaller sample size 256 
meant there was less evidence for this result (p=0.139). Paternal asthma also showed association 257 
with the early-onset-late-resolving class (OR=2.53 (95% CI 1.30-4.91) p=0.006). In PIAMA the 258 
associations with maternal and paternal history of asthma were similar, with strong associations 259 
with the persistent and early-onset-late-resolving groups for maternal history (OR=1.94 (95% CI 260 
1.11-3.40) p=0.021, OR=3.14 (95%CI 1.76-5.61) p=1x10
-4
, respectively) and with the persistent group 261 
for paternal history (OR=2.69 (95% CI 1.66-4.36) p=6x10
-5
). 262 
In ALSPAC, breastfeeding was associated with a higher risk of persistent and early-onset-late-263 
resolving AD (OR=1.42 (95% CI 1.11-1.81) p=0.006; OR=1.53 (95% CI 1.12-2.08) p=0.008, 264 
respectively). There was little evidence of association with mid- or late-onset classes. In PIAMA, 265 
there was little evidence for breastfeeding being associated with any class. 266 
Early-life exposure to a pet cat was not associated with any of the latent classes in the primary 267 
analyses for ALSPAC or PIAMA. However this was the only risk-factor in which a difference was seen 268 
in the complete-case results in ALSPAC, where there was some evidence of a protective effect of 269 
early-life cat exposure on the early-onset-early-resolving class only (OR=0.64 (95% CI 0.46-0.90) 270 
p=0.010, Table E9, Online Repository). The same direction of effect was observed in PIAMA but with 271 
a weaker and less precise estimate (OR=0.72 (95% CI 0.50-1.04) p=0.081).  272 
Associations between latent classes and atopic traits and comorbidities 273 
The associations of AD classes with elevated total IgE and asthma are displayed in Table III. Raised 274 
IgE was associated with the AD classes showing prevalent disease at the time of testing, i.e. 7-8 years 275 
of age (the persistent, early-onset-late-resolving and mid-onset classes in ALSPAC and the persistent 276 
class in PIAMA). 277 
In ALSPAC, all classes showed association with asthma at 7 and 13 years of age. The associations 278 
were strongest for the persistent class (7 years OR=4.94, p=7x10
-51
; 13 years OR=6.04 p=3x10
-56
) in 279 
which 29% reported asthma at 7 years of age (compared to 8% of the normal/transiently affected 280 
class), increasing to 31% at 13 years (compared to 7% of the normal/transient class). The early-281 
onset-early-resolving class showed the smallest increased risk of asthma at 7 and 13 years of age 282 
(ORs 1.52 and 1.72, respectively). In PIAMA the persistent and early-onset-late-resolving group 283 
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showed association with asthma at age 7 (persistent OR=9.86 p=3x10
-10
). At age 11-12 years all but 284 
the mid-onset-resolving group were associated, again the strongest association being with the 285 
persistent group (OR=9.61 p=2x10
-9
). 286 
Associations between latent classes and genetic risk variants 287 
In ALSPAC, all classes other than the mid-onset class showed association with FLG null mutations 288 
(Table IV). The strongest association was for the persistent group (OR=4.31 (95% CI 3.29-5.63) 289 
p=2x10
-26
); the other associated classes had ORs of about half this (2.14-2.30). In PIAMA only the 290 
early-onset-late-resolving class was associated with FLG null mutations (OR=5.63 (95% CI 2.65-11.95) 291 
p=7x10
-6
), however the approximate number of FLG
-/+ 
or FLG 
-/-
 individuals in the PIAMA analyses 292 
were very low (between 7 and 14 individuals per class), so power was limited to identify 293 
associations. 294 
The combined genetic risk score encompassing all other AD variants was associated with all but the 295 
early-onset-early-resolving and the late-onset classes in the 6-class model in ALSPAC. The association 296 
was strongest with the persistent class (OR=1.17 (95% CI 1.12-1.22) for each additional risk allele, 297 
p=2x10
-13
). A similar pattern was observed in PIAMA, with the persistent class showing the strongest 298 
association and an almost identical effect size to that seen in ALSPAC (OR=1.17 (95% CI 1.07-1.28) 299 
p=5x10
-4
). 300 
The associations for individual AD risk SNPs are shown in Table E11 (Online Repository). These 301 
analyses are not well powered and should be interpreted with caution, but some patterns are 302 
noteworthy.  Most variants had the strongest effects in the persistent class and three variants 303 
showed consistent associations in ALSPAC and PIAMA: These were rs17881320 in STAT3, rs479844 304 
near OVOL1 and rs6010620 in RTEL1. One variant (rs1057258) showed evidence in ALSPAC for 305 
association in the opposite direction to that reported previously for AD with the late-onset and 306 
early-onset-early-resolving classes (OR=0.73 (95% CI 0.57-0.93) p=0.011; OR=0.80 (95% CI 0.65-0.99) 307 
p=0.039, respectively). A consistent direction of effect (though with weak statistical evidence) was 308 
observed for the late-onset class and this SNP in PIAMA (OR=0.74 (95% CI 0.45-1.20) p=0.218).  309 
  310 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Discussion 311 
Our results provide novel insights into the heterogeneity of AD in childhood. We report six latent 312 
classes, representing subphenotypes of AD with remarkable consistency between two independent 313 
cohorts. The most prevalent class was early-onset-early-resolving AD (13-15%), which was 314 
associated with male gender. This class has a favourable prognosis and is only very weakly 315 
associated with asthma in later life. Two classes of persistent disease were identified (early-onset-316 
persistent and early-onset-late-resolving);  these were most strongly associated with an AD genetic 317 
risk score as well as personal and parental history of atopic disease. Importantly, these classes 318 
display strong comorbidity with asthma. A yet unrecognised class of mid-onset-resolving AD, not 319 
associated with FLG mutations, but strongly associated with asthma, was described. In this class AD 320 
prevalence increases sharply from 2.5 years of age peaking at ~6 years. The aetiological factors in 321 
this class remain unclear because the subgroup was not strongly associated with many of the known 322 
risk factors, but does show strong association with asthma comorbidity.  323 
The clinical application of this LLCA is based on the clear demonstration of distinct classes of AD 324 
phenotype with different disease trajectories. The substantial diversity of disease which is defined as 325 
‘AD’ (or ‘eczema’) has long been recognised, and clearer subdivisions are an essential prerequisite 326 
for the development of stratified medicine approaches which will be needed for the optimal 327 
application of novel biological therapies in the more severe subgroups of AD.  Therefore, further 328 
studies are needed to define the most appropriate combinations of biomarkers and risk factors to 329 
detect these subgroups prospectively and at an early age.  330 
There was some evidence of differential strength and presence of associations with risk factors and 331 
comorbidities between the classes. The early-onset-persistent class showed the strongest 332 
associations (compared to other classes) with the majority of well-established risk factors and 333 
markers of severe atopic phenotype, including FLG null mutations and a genetic risk score of other 334 
AD-associated variants, co-existent asthma and elevated IgE and parental history of atopic disease. 335 
The associations with asthma at ages 7 and 11-13 years were strongest with the persistent class, but 336 
all AD classes showed evidence of some increased risk of asthma at these ages. Our data did not 337 
support the presence of a specific trajectory from AD to asthma (the so-called atopic march), which 338 
is in keeping with a previous report from the MAAS study and earlier analyses in ALSPAC
22
. The 339 
associations observed with elevated total IgE were most marked during active and persistent 340 
disease, in keeping with previous reports
23
. Within the class of early onset disease that resolved 341 
before the time of IgE measurement, a smaller proportion of individuals had IgE levels above the 342 
threshold defined as ‘elevated’, in comparison with the class of early onset disease that was still 343 
active. Further investigation with earlier IgE measures are required to explore whether such 344 
individuals would have had raised IgE at the time of active disease. 345 
Whilst being female was more strongly associated with the early-onset persistent and late-onset 346 
classes, there was some evidence that being male was differentially associated with early-onset-347 
resolving classes. It is tempting to speculate that the late-onset class might represent AD induced by 348 
behavioural changes in the adolescent child (including increased bathing/showering and the use of 349 
fragranced products) which might differ between males and females, but this hypothesis remains to 350 
be tested. The male preponderance in AD cases ascertained in infancy has previously been 351 
reported
24-27 
but the mechanisms accounting for this gender difference are unknown.  352 
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There is conflicting epidemiological evidence indicating that breastfeeding may be either a risk factor 353 
or protective factor in the aetiology of AD
28
 and our analyses have not been able to add clarity to 354 
this important question. In the ALSPAC cohort, breastfeeding was associated with the two classes of 355 
most long-lasting disease (early-onset-persistent and early-onset-late-resolving AD) but in the 356 
PIAMA cohort there was little evidence of breastfeeding being associated with any of the latent 357 
classes. This apparent difference could be explained in several different ways: It may be stochastic, 358 
(given that all 95%CIs overlap between the two cohorts); it may be a result of the substantially 359 
higher prevalence of breastfeeding in the Dutch population compared with the UK; or it may result 360 
from reverse causation in the ALSPAC cohort, if, for example, mothers with a strong history of atopic 361 
disease are more likely to breastfeed their infants.   362 
We found little evidence for early-life exposure to a pet cat being associated with any of the classes 363 
in the main analysis. However, in the complete-case dataset in ALSPAC there was some evidence 364 
that cat exposure may have a protective effect on early-onset-early-resolving AD, which is somewhat 365 
at odds with previous reports of cat exposure increasing the risk of AD
29,30
. This may indicate a 366 
specific beneficial effect of early cat exposure on this more transient phenotype and warrants 367 
further investigation. 368 
There was evidence that FLG null mutations were associated with all classes, however, as reported 369 
previously
31,32
, the association was strongest in the group with early-onset-persistent disease. The 370 
genetic risk score of the other established AD variants showed a similar pattern, whereby the 371 
association was strongest for the early-onset-persistent class, with a striking increase in burden of 372 
risk of approximately 17% per additional risk allele. Of note, three variants showed consistent 373 
patterns of effects across both cohorts, with stronger associations in the early-onset persistent 374 
group, and weaker associations with the other classes. The functional mechanisms of these loci have 375 
not been fully defined, but rs17881320 is within STAT3 (encoding a signal transducer and activator of 376 
transcription, an acute phase response protein); rs479844 is near to OVOL1 (which encodes zinc-377 
finger containing transcription factor); and rs6010620 is within RTEL1 (regulator of telomere 378 
elongation helicase 1). This heterogeneity of effect of genetic variants on different disease profiles, 379 
emphasises the need for patient stratification in future genetic studies. Stratification may be used to 380 
increase the power to detect variants associated with specific classes; stratification could also allow 381 
the identification of phenotype-specific mechanistic pathways as future therapeutic targets.  382 
The similarity and high frequency of AD symptom ascertainment in ALSPAC and PIAMA are strengths 383 
of our study. The phenotype definitions used within the cohorts comprised prospective questions to 384 
capture diagnostic features of eczema including the changing distribution of skin involvement from 385 
infancy to later childhood. One key difference is that PIAMA had shorter follow-up (11 years versus 386 
16 years), which could have limited the ability to detect classes with differences at later ages. 387 
Despite this, the class patterns are remarkably similar between ALSPAC and PIAMA (Figure 2). 388 
However, neither cohort allowed for investigation of variable AD patterns in adulthood, more subtle 389 
AD patterns (such as the transient cases which were indistinguishable from the unaffected 390 
individuals in our study) nor in people of ancestries other than white European. We also studied only 391 
a limited number of environmental factors and so this work could be extended to investigate the 392 
association between latent classes and other potential risk factors. 393 
Although individuals are not assigned to classes with complete certainty (Table E8), the LLCA 3-step 394 
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method models this uncertainty and allows for inclusion of individuals with incomplete data to 395 
maximise sample size and minimise any loss to follow up bias. We note that our analysis does not 396 
formally test for causal direction and some risk factors studied do not entirely precede the onset of 397 
disease. Therefore, although the observational associations are interesting, further work should be 398 
conducted to investigate causality. A further challenge is that by stratifying AD into smaller 399 
subphenotypes of disease, we inevitably lower the power of association testing. Few studies have 400 
such detailed longitudinal data and so in order to increase sample sizes in future studies, it will be 401 
necessary to extrapolate these data-driven phenotypes into settings where less detailed data are 402 
available, such as large data registries
33
. 403 
In conclusion, we have identified longitudinal subgroups of AD which have both shared and distinctly 404 
different risk factor profiles. Future studies of the aetiology and treatment of this complex trait 405 
should take these subgroups of disease into account and in turn this may offer valuable stratified 406 
medicine approaches to refining prognostic predictions and therapeutic strategies. 407 
  408 
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Figure Legends 514 
Figure 1. Prevalence and frequency of AD in UK and Dutch longitudinal cohorts. Plot of frequency 515 
(right hand axis) of AD cases (grey bars) and controls (white bars) and AD prevalence (black points & 516 
left hand axis) over 12 time points in ALSPAC and 10 time points in PIAMA. AD is defined by presence 517 
of typical rash. 518 
Figure 2. Longitudinal classes identified using LLCA in two independent birth cohorts, (A) ALSPAC 519 
(n=9894), (B) PIAMA (n=3652).  520 
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Tables 
Table I. Descriptions and prevalences of the classes in two independent cohorts. 
Class Description of class in ALSPAC ALSPAC prevalence PIAMA prevalence 
Unaffected 
individuals or 
transient AD 
64% of this class never had reported rash, others had one or two isolated 
occasions of rash; ~10% reported rash consistent with AD at 6-18 months and 
this declined with age. 
58.0% 
 
62.9% 
Early-onset-
persistent AD 
At 30 months of age ~85% of this class had reported rash, increasing to >90% 
prevalence until 12 years; it then steadily declined to ~50% at 16.5 years. 
7.3% 
 
4.9% 
Early-onset-late-
resolving AD 
In this class the prevalence of rash rose steeply to >95% at 30 months and then 
steadily declined to ~10% by 16.5 years. 
7.0% 
 
3.8% 
Early-onset-early-
resolving AD 
~60% of children in this class had reported rash at 18 and 30 months, this 
declined to 10% by 6-7 years. 
12.9% 
 
15.4% 
Mid-onset-resolving 
AD 
In this class there was a 10-20% prevalence of rash until 30 months, steeply 
rising to 75% prevalence 5-6 years, and steadily declining to <10% prevalence 
by 16.5 years. 
7.0% 
 
6.5% 
Late-onset-resolving 
AD 
In this class approximately 30% reported rash at 18 months, declining to ~10% 
prevalence at 5-6 years, steadily rising to ~70% prevalence by 12 years and 
finally declining to 10% by 16.5 years. 
7.9% 
 
6.5% 
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Table II. Association results between risk factors and AD classes identified by LLCA. 
Trait 
Exposed / 
Total 
Wald 
P 
Early-onset 
persistent 
Early-onset  
late-resolving 
Early-onset  
early-resolving 
Mid-onset  
resolving 
Late-onset  
resolving 
ALSPAC     7.3% 7.0% 12.9% 7.0% 7.9% 
Female 
 
4805/9875 
 
6E-17 
 
1.56(1.29-1.89) 
p=6E-6 
0.97(0.77-1.22) 
p=0.811 
0.75(0.62-0.91) 
p=0.004 
1.79(1.40-2.29) 
p=4E-6 
1.90(1.48-2.44) 
p=4E-7 
Maternal eczema 
 
3154/9722 
 
3E-43 
 
3.16(2.60-3.83) 
p=4E-31 
1.68(1.32-2.14) 
p=2E-5 
2.00(1.65-2.44) 
p=4E-12 
1.66(1.29-2.13) 
p=8E-5 
1.75(1.36-2.25) 
p=1E-5 
Maternal asthma 
 
1554/9721 
 
2E-4 
 
1.54(1.22-1.95) 
p=3E-4 
1.43(1.08-1.91) 
p=0.014 
1.23(0.95-1.58) 
p=0.112 
1.10(0.79-1.53) 
p=0.566 
1.02(0.73-1.44) 
p=0.891 
Paternal asthma 
 
245/1568 
 
0.030 
 
1.59(0.86-2.93) 
p=0.139 
2.53(1.30-4.91) 
p=0.006 
1.58(0.86-2.89) 
p=0.139 
0.94(0.38-2.33) 
p=0.893 
1.72(0.83-3.57) 
p=0.146 
Breastfeeding 
 
7019/9198 
 
9E-4 
 
1.42(1.11-1.81) 
p=0.006 
1.53(1.12-2.08) 
p=0.008 
1.22(0.97-1.54) 
p=0.093 
1.04(0.78-1.37) 
p=0.803 
1.04(0.78-1.38) 
p=0.800 
Pet cat 
 
2963/9511 
 
0.179 
 
0.88(0.71-1.09) 
p=0.226 
1.14(0.89-1.45) 
p=0.291 
0.92(0.74-1.13) 
p=0.427 
0.81(0.61-1.06) 
p=0.125 
1.26(0.98-1.62) 
p=0.073 
PIAMA     4.9% 3.8% 15.4% 6.5% 6.5% 
Female 
 
1759/3652 
 
0.025 
 
1.06(0.75-1.49) 
p=0.743 
0.63(0.40-1.00) 
p=0.051 
0.89(0.64-1.24) 
p=0.494 
0.94(0.65-1.37) 
p=0.753 
1.87(1.21-2.90) 
p=0.005 
Maternal asthma 
 
259/3645 
 
0.001 
 
1.94(1.11-3.40) 
p=0.021 
3.14(1.76-5.61) 
p=1E-4 
1.33(0.70-2.51) 
p=0.385 
0.96(0.41-2.24) 
p=0.932 
1.38(0.65-2.93) 
p=0.406 
Paternal asthma 
 
272/3633 
 
0.002 
 
2.69(1.66-4.36) 
p=6E-5 
0.91(0.34-2.46) 
p=0.854 
1.19(0.63-2.25) 
p=0.585 
1.72(0.94-3.14) 
p=0.076 
1.17(0.53-2.61) 
p=0.697 
Breastfeeding 
 
2984/3614 
 
0.888 
 
1.00(0.63-1.56) 
p=0.983 
1.34(0.70-2.57) 
p=0.377 
1.19(0.75-1.89) 
p=0.461 
0.97(0.60-1.56) 
p=0.886 
0.88(0.52-1.48) 
p=0.634 
Pet cat 
 
1213/3651 
 
0.151 
 
0.73(0.50-1.06) 
p=0.098 
0.80(0.50-1.29) 
p=0.367 
0.72(0.50-1.04) 
p=0.081 
1.00(0.68-1.47) 
p=0.996 
0.67(0.42-1.07) 
p=0.094 
‘Wald P’ is for the overall omnibus test. Individual p-values and effect sizes comparing each class with the ‘unaffected/transient’ class are also shown; 
results p<0.05 are shown in bold.  
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Table III. Association results between AD classes identified by LLCA and comorbidities. 
Trait 
Cases / 
Total Wald P 
Early-onset 
persistent 
Early-onset  
late-resolving 
Early-onset   
early-resolving 
Mid-onset 
resolving 
Late-onset 
resolving 
ALSPAC     7.3% 7.0% 15.4% 7.0% 7.9% 
asthma at 7 
years of age 
904/7859 2x10
-50
 
5.50(4.28-7.05) 
p=5x10
-41
 
3.08(2.22-4.27) 
p=2x10
-11
 
1.56(1.09-2.24) 
p=0.015 
2.23(1.53-3.26) 
p=3x10
-5
 
1.89(1.26-2.83) 
p=0.002 
        asthma at 13 
years of age 
784/6752 7x10
-58
 
7.19(5.48-9.42) 
p=3x10
-46
 
3.59(2.51-5.12) 
p=2x10
-12
 
1.79(1.20-2.65) 
p=0.004 
3.41(2.35-4.96) 
p=1x10
-10
 
2.01(1.30-3.12) 
p=0.002 
        Elevated IgE at  
7 years of age 
2057/4790 8x10
-16
 
2.62(1.98-3.47) 
p=1x10
-11
 
1.92(1.38-2.68) 
p=1x10
-4
 
1.15(0.88-1.51) 
p=0.310 
1.55(1.10-2.18) 
p=0.013 
1.38(0.99-1.93) 
p=0.059 
PIAMA     4.9% 3.8% 15.4% 6.5% 6.5% 
asthma at 7 
years of age 
94/3349 2x10
-15
 
14.27(7.33-27.78) 
p=5x10
-15
 
5.92(2.31-15.16) 
p=2x10
-4
 
3.03(1.08-8.47) 
p=0.035 
0.60(0.03-13.62) 
p=0.750 
1.73(0.38-7.88) 
p=0.478 
        asthma at 11 
years of age 
102/2639 7x10
-11
 
15.35(6.86-34.35) 
p=3x10
-11
 
9.12(3.49-23.82) 
p=6x10
-6
 
4.91(1.66-14.55) 
p=0.004 
2.10(0.42-10.53) 
p=0.366 
5.70(1.98-16.43) 
p=0.001 
        Elevated IgE at  
8 years of age 
723/1707 1x10
-4
 
3.00(1.85-4.86) 
p=8x10
-6
 
1.58(0.86-2.89) 
p=0.140 
1.57(0.97-2.56) 
p=0.067 
1.42(0.83-2.46) 
p=0.203 
0.97(0.53-1.77) 
p=0.914 
‘Wald P’ is for the overall omnibus test. Individual p-values and effect sizes comparing each class with the ‘unaffected/transient’ class are also shown; 
elevated IgE is defined as total IgE >75kU/L; results p<0.05 are shown in bold.  
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Table IV. Association results between genetic risk factors and AD classes identified by LLCA. 
  
# with risk 
genotype / total Wald P 
Early-onset 
persistent 
Early-onset  
late-resolving 
Early-onset   
early-resolving 
Mid-onset 
resolving 
Late-onset 
resolving 
ALSPAC     7.3% 7.0% 12.9% 7.0% 7.9% 
FLG null mutation 813/7570 4x10
-28
 131/570 (23%)* 78/514 (15%)* 111/832 (13%)* 54/467 (12%)* 70/499 (14%)* 
   
4.31(3.29-5.63) 
p=2x10
-26
 
2.23(1.53-3.26) 
p=3x10
-5
 
2.14(1.54-2.98) 
p=7x10
-6
 
1.48(0.92-2.39) 
p=0.109 
2.30(1.57-3.38) 
p=2x10
-5
 
        Genetic risk score 
(all other variants) 
total N=6497 
 
8x10
-17 
 
1.17(1.12-1.22) 
p=2x10
-13
 
1.08(1.04-1.13) 
p=4x10
-4
 
1.02(0.99-1.06) 
p=0.222 
1.06(1.00-1.12) 
p=0.042 
1.01(0.96-1.06) 
p=0.758 
PIAMA     4.9% 3.8% 15.4% 6.5% 6.5% 
FLG null mutation 117/1516 6x10
-4
 7/74 (10%)* 14/60 (23%)* 11/159 (7%)* 7/96 (7%)* 10/95 (11%)* 
   
1.34(0.49-3.67) 
p=0.563 
5.63(2.65-11.95) 
p=7x10
-6
 
0.87(0.25-3.03) 
p=0.821 
0.95(0.26-3.45) 
p=0.942 
1.87(0.76-4.62) 
p=0.174 
        Genetic risk score 
(all other variants) 
total N=1964 
 
6x10
-5
 
 
1.17(1.07-1.28) 
p=5x10
-4
 
1.00(0.91-1.11) 
p=0.968 
1.16(1.08-1.25) 
p=1x10
-4
 
1.11(1.03-1.20) 
p=0.004 
1.08(0.98-1.18) 
p=0.111 
‘Wald P’ is for the overall omnibus test. Individual p-values and effect sizes comparing each class with the ‘unaffected/transient’ class are also shown; 
results p<0.05 are shown in bold; Genetic risk score is defined by total number of risk alleles across the 23 AD-associated loci (other than FLG) identified by 
GWAS meta-analysis to date; OR represents the change in odds per risk allele for the genetic risk score or between carriers compared to non-carriers for 
the FLG mutations. 
* In order to demonstrate approximate numbers of individuals with FLG null mutations in each class, individuals were assigned to most likely class. Given 
that the actual association analysis accounted for uncertainty in assignment of classes, these values are approximations for purposes of highlighting where 
power might be low. The approximate number with FLG null mutations / approximate total with FLG genotype data (%), within each class are shown. The 
‘unaffected/transient’ groups had 8% (approx. 369/4712) and 7% (approx. 68/1032) with FLG mutations in ALSPAC and PIAMA, respectively. 
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Online Repository 
The Avon Longitudinal Study of Parents and Children (ALSPAC) 
This population-based birth cohort recruited 15,247 pregnant women resident in Avon, UK with 
expected dates of delivery from 1st April 1991 to 31st December 1992, resulting in 14,775 live births 
and 14,701 children who were alive at 1 year of age. Enrolment is described in detail in the cohort 
profile papers
1,2
 and the study website contains details of all the data that are available through a 
fully searchable data dictionary
3
. Biological samples including DNA have been collected for 10,121 of 
the children from this cohort. Ethical approval for this study was obtained from the ALSPAC Ethics 
and Law Committee and the Local Research Ethics Committees; written informed consent was 
provided by the parents/guardians. 
DNA was obtained from blood samples using standard extraction techniques. The 4 most prevalent 
loss of function mutations in the gene encoding filaggrin (FLG) R501X, 2282del4, R2447X and S3247X 
were genotyped using KASP
TM
 genotyping technology
4
 (LGC Genomics, Hoddesdon, Hertfordshire, 
UK). Genome-wide genotyping was undertaken in 9912 children using the Illumina HumanHap550 
quad SNP genotyping platform by 23andMe (Mountainview, California, USA), subcontracting to the 
Wellcome Trust Sanger Institute (Cambridge, UK) and the Laboratory Corporation of America 
(Burlington, NC, USA). Genotypes were imputed with Impute2 using 1000 Genomes phase 1 version 
3 as a reference set as previously described
5
.  
 
 
Prevention and Incidence of Asthma and Mite Allergy birth cohort study (PIAMA) 
The PIAMA study is a Dutch multicenter birth cohort that invited allergic and nonallergic pregnant 
women to participate; 4146 (53%) agreed and provided written informed consent (1327 allergic and 
2819 nonallergic subjects). 183 were lost to follow-up before any data were obtained, so the study 
started with 3963 new-borns. Parents were sent International Study of Asthma and Allergies in 
Childhood–based questionnaires about their child’s health, including asthma and eczema symptoms 
at 3, 12, 24, 36, 48, 60, 72, 84, 96 and 132 months after birth. All high-risk children and a sample of 
low-risk children were invited for clinical examinations at 4 years of age and at 8 years all children 
who were still in the study were invited. Full details of the study have been published previously
6
. 
The study protocol was approved by the medical ethics committees of the participating institutions 
and informed written parental consent was obtained for each participant. 
Blood samples were collected from the children at age 4 and 8 years for DNA extraction. Children 
who did not participate in a clinical examination were invited to send a buccal swab by mail, and 
DNA was extracted from buccal swabs as described previously
7
. DNA was obtained from 2,162 
children. Genome-wide genotyping was performed in three phases. The first phase was performed 
within the framework of the GABRIEL Consortium using an Illumina Human 610K quad array
8
. 
Genotypes were available from 172 children with asthma and from 187 controls after quality 
control. A second group of 268 children who were more extensively examined during follow up were 
genotyped with the Illumina HumanOmniExpress array. A final group of 1377 children was 
genotyped with the Illumina Human Omni Express Exome Array.  SNPs were harmonized by base pair 
position annotated to genome build 37, name and annotation of strand for each platform. 
Discordant or duplicate SNPs or SNPs that showed large differences in allele frequencies (>15%) 
were removed. After quality control, a total of 1968 individuals remained and imputation was 
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performed per platform using IMPUTE 2.07 against the reference data set of the CEU panel of the 
1000 Genomes project (version March 2012). SNPs of high quality (info-score IMPUTE ≥ 0.7) were 
merged into one dataset using GTOOL and used for further analysis. Dosages of imputed SNPs were 
predicted based on the following assumptions; 0 is the first homozygote, 0.5 is a heterozygote and 1 
is the other homozygote. The info scores of the imputed SNPs were all ≥0.99 which provided reliable 
dosages estimates. From this dataset, 22 genotypes were available to calculate genetic risk scores 
for further analysis. Prevalent FLG loss-of-function mutations were genotyped at LGC Genomics as 
described above for the ALSPAC cohort.  
 
LLCA – selection of best model 
Longitudinal latent class analysis was carried out in Mplus. Models with between 2 and 7 classes 
were tested. Bayesian Information Criterion (BIC), entropy, and p-values from the Vuong-Lo-
Mendell-Rubin (VLMR) likelihood ratio tests were compared to ascertain the models with the best 
fit. 
 
 
ALSPAC – model fit 
In the dataset of complete data (N=3480), the BIC (which is penalized for model complexity) was 
lowest for a 6 class model (Table E1 and Fig E1a) and the VLMR LR p-value showed evidence of 
improved fit for the 6-class model compared to a 5-class model (p=0.018). Entropy remained above 
0.8 in all models, indicating good class delineation and individual class classifications were all >0.75, 
with <0.11 for all off-diagonals. The largest decrease in the BIC were seen from 2 to 4 classes (Fig 
E1a), with only small improvement in model fit between the 4- and 6-class models. 
 
9894 individuals had data available from at least 6 of the 12 time points and the model fit 
parameters were broadly consistent with the smaller but more complete dataset (Table E1 and Fig 
E1b). The entropies for the 4- and 6-class models were 0.78 and 0.75, respectively indicating only 
small decreases in model fit compared to the smaller, but complete analysis and the individual 
classifications for each class, were all >0.7, with <0.13 for all off-diagonals. Comparison of results 
from the larger incomplete and smaller but complete datasets showed similar class assignment: only 
3% of children changed best-fit class between the 6-class models in each analysis (Table E2) and the 
proportions of individuals in each class are very similar between models (Table E3) 
 
Moving from the 6-class to the 4-class model, 99% of the persistent class (733/739) and the normal 
class (6111/6168) remained in these classes in the 4 class model. The majority of the early-onset-
early-resolving (81%) and early-onset-late-resolving (61%) were in the 4-class early-onset class. The 
majority of the mid-onset (49%) and late-onset (87%) were in the 4-class late-onset class (Table E4). 
 
 
PIAMA – model fit 
In the dataset of complete data (N=2063), the BIC was lowest for a 4 class model (Table E5 & Fig E2a) 
and the VLMR LR p-value showed evidence of improved fit for the 4-class model compared to a 3-
class model (p=0.015). However, there was only a small increase in BIC in the 6 class model (Table E5 
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& Fig E2a).  
3652 individuals had data available from at least 5 of the 10 time points and the model fit 
parameters were broadly consistent with the smaller but more complete dataset (Table E5 and Fig 
E2b). The entropies for the 4- and 6-class models were 0.76 and 0.81, respectively indicating only 
small decreases in model fit compared to the smaller, but complete analysis and the proportions of 
individuals in each class are similar between the incomplete and complete analyses (Table E6). 
Moving from the 6-class to the 4-class model, similar to ALSPAC, 99% of the persistent class 
(178/180) and the normal class (2468/2497) remained in these classes in the 4 class model. The 
majority of the early-onset-early-resolving (51%) and early-onset-late-resolving (68%) were in the 4-
class early-onset class. The majority of the mid-onset (55%) and late-onset (91%) were in the 4-class 
late-onset class (Table E7). 
 
Average latent class probability assignments 
Average latent class probability assignments were >70% for all classes in the ALSPAC and PIAMA final 
models (Table E8). Unaffected and persistent classes had the highest probabilities (>80% in all 
cases). The largest probabilities for alternative class membership were between persistent and early-
onset later-resolving in ALSPAC (12%) and early-onset early-resolving an unaffected in PIAMA (18%). 
 
Bias –adjusted three step method for testing association of covariates with latent classes. 
Association of risk factors and comorbidities with the latent classes were tested using a bias-
adjusted three step analysis
9
 to account for uncertainty in class assignment. 
Following the LLCA (step 1), class assignment probabilities were exported to Stata version 14-MP
10
 
and logit constraints were derived to define the relationship between modal (or best) class (W) and 
latent classes (X) (which account for the uncertainty in modal class) (step 2). These logit constraints 
were then used in regression analyses in MPlus (step 3). 
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Figure Legends 
Fig E1. Bayesian Information Criterion for ALSPAC model fit. (a) smaller dataset with complete data 
(N=3480), (b) larger dataset with ≥6 of the 12 time-points available (N=9894). 
Fig E2. Bayesian Information Criterion across all PIAMA models, for (a) individuals with complete 
data (N=2063), and (b) individuals with incomplete data (N=3652)  
 
Fig E3. 4-class model in ALSPAC 
 
Fig E4. 4-class model in PIAMA 
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Tables 
Table E1. LLCA model fit parameters in the ALSPAC cohort  
  Individuals with complete data 
(N=3480)  
 Individuals with ≥6/12 time points 
available (N=9894) 
Number of 
classes 
BIC Entropy VLMR LRT  
p-value 
 BIC Entropy VLMR LR p-
value 
2 33643 0.91 <0.0001  78475 0.88 <0.0001 
3 32580 0.83 <0.0001  76525 0.79 <0.0001 
4 32182 0.83 <0.0001  75655 0.78 <0.0001 
5 32083 0.80 0.0394  75386 0.77 <0.0001 
6 32035 0.80 0.0177  75288 0.75 0.1289 
7 32049 0.80 0.0449  75212 0.75 0.0001 
BIC, Bayesian Information Criterion; VLMR LRT, Vuong–Lo–Mendell–Rubin Likelihood ratio test. The 4- and 6-class models 
(in bold), both showed evidence of good model fit; the 6-class model had the lowest BIC value, but this was only a minor 
improvement in model fit compared to the 4-class model, according to VLMR LRT. 
 
Table E2. Comparison of ALSPAC 6 class models constructed with individuals with complete data and 
constructed with individuals with incomplete data  
           incomplete 
 
complete 
P EO-LR EO-ER MO-R LO-R unaffected 
P 282 0 0 0 1 0 
EO-LR 0 264 4 8 0 0 
EO-ER 0 7 387 20 4 26 
MO-R 5 0 0 193 3 1 
LO-R 0 2 4 6 246 17 
unaffected 0 0 0 6 2 1992 
Incomplete data represents at least 6 of the 12 time-points available; the majority of individuals (diagonals, 97%) do not 
change classes; 116/3480 (3%) change classes. 
In order to carry out this comparison individuals were assigned to their most likely class for the two models. Given that 
entropies are only 0.75-0.8, this is an approximation. 
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Table E3. Comparison of proportion of individuals in ALSPAC 6 class models constructed with 
complete data and constructed with individuals with incomplete data 
Class Incomplete analysis Complete analysis 
P 7.3% 7.9% 
EO-LR 7.0% 8.1% 
EO-ER 12.9% 14.5% 
MO-R 7.0% 6.0% 
LO-R 7.9% 8.7% 
unaffected 58.0% 54.9% 
 
Table E4. Comparison of ALSPAC 4- & 6-class models constructed with individuals with at least 6 of 
the 12 time-points available.  
               4 class 
6 class 
P EO-R LO-R unaffected 
P 733 2 4 0 
EO-LR 246 401 11 0 
EO-ER 0 876 2 206 
MO-R 64 238 296 3 
LO-R 12 23 545 45 
unaffected 0 14 43 6111 
In order to carry out this comparison individuals were assigned to their most likely class for the two models. Given that 
entropies are only 0.75-0.78, this is an approximation. 
 
Table E5. LLCA model fit parameters in the PIAMA cohort  
 Individuals with complete data 
(N=2063) 
 Individuals with ≥5/10 time points available 
(N=3652) 
Classes BIC Entropy VLMR LR p-
value 
 BIC Entropy VLMR LR p-
value 
2 14395 0.92 <0.0001  23850 0.91 <0.0001 
3 14147 0.83 <0.0001  23476 0.82 <0.0001 
4 14067 0.84 0.0146  23327 0.81 0.0139 
5 14076 0.76 0.0888  23303 0.76 0.0675 
6 14105 0.73 0.0228  23312 0.76 0.0751 
7 14141 0.71 0.3658  23343 0.78 0.0057 
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Table E6. Comparison of proportion of individuals in PIAMA 6 class models constructed with 
complete data and constructed with individuals with incomplete data 
Class Incomplete analysis Complete analysis 
P 4.9% 4.8% 
EO-LR 3.8% 4.5% 
EO-ER 15.4% 12.4% 
MO-R 6.5% 8.7% 
LO-R 6.5% 11.8% 
unaffected 62.9% 57.8% 
 
Table E7. Comparison of PIAMA 4 & 6 class models constructed with individuals with at least 5 of 
the 10 time-points available.  
              4 class 
6 class 
P EO-R LO-R unaffected 
P 178 0 2 0 
EO-LR 44 98 2 0 
EO-ER 0 203 6 191 
MO-R 26 76 126 0 
LO-R 1 5 184 13 
unaffected 0 0 29 2468 
In order to carry out this comparison individuals were assigned to their most likely class for the two models. Given that 
entropies are only 0.76-0.81, this is an approximation. 
 
Table E8. Average latent class probabilities for the most likely class membership (row) by latent 
class (column).  
ALSPAC PIAMA 
P EO-LR EO-ER MO-R LO-R UA P EO-LR EO-ER MO-R LO-R UA 
P 0.834 0.122 0.004 0.030 0.009 0.000 0.902 0.047 0.000 0.042 0.009 0.000 
EO-LR 0.093 0.718 0.094 0.076 0.019 0.001 0.042 0.764 0.092 0.075 0.025 0.002 
EO-ER 0.004 0.069 0.735 0.047 0.047 0.098 0.001 0.031 0.718 0.032 0.043 0.175 
MO-R 0.042 0.048 0.070 0.716 0.081 0.043 0.03 0.022 0.081 0.739 0.084 0.044 
LO-R 0.016 0.023 0.061 0.097 0.722 0.082 0.02 0.012 0.066 0.083 0.717 0.103 
UA 0.000 0.001 0.054 0.012 0.034 0.898 0.000 0.000 0.092 0.008 0.021 0.879 
UA=unaffected 
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Table E9. Association results for all four LCA models in ALSPAC (incomplete/complete & 4-/6-class models)
INCOMPLETE CASE 6 CLASS INCOMPLETE CASE 4 CLASS
N omni_p Early-onset persistent Early-onset late-resolving Early-onset  early-resolving Mid-onset resolving Late-onset resolving omni_p Early-onset persistent Early-onset resolving Late-onset resolving
7.3% 7.0% 12.9% 7.0% 7.9% 10.7% 16.5% 10.9%
female 9875 6E-17 1.56(1.29-1.89) p=6E-6 0.97(0.77-1.22) p=0.811 0.75(0.62-0.91) p=0.004 1.79(1.40-2.29) p=4E-6 1.90(1.48-2.44) p=4E-7 2E-12 1.44(1.24-1.67) p=1E-6 0.94(0.81-1.09) p=0.393 1.96(1.60-2.39) p=4E-11
maternal eczema 9722 3E-43 3.16(2.60-3.83) p=4E-31 1.68(1.32-2.14) p=2E-5 2.00(1.65-2.44) p=4E-12 1.66(1.29-2.13) p=8E-5 1.75(1.36-2.25) p=1E-5 3E-41 2.46(2.12-2.85) p=2E-32 1.87(1.60-2.17) p=5E-16 1.65(1.35-2.02) p=1E-6
maternal asthma 9721 2E-4 1.54(1.22-1.95) p=3E-4 1.43(1.08-1.91) p=0.014 1.23(0.95-1.58) p=0.112 1.10(0.79-1.53) p=0.566 1.02(0.73-1.44) p=0.891 5E-4 1.41(1.17-1.70) p=4E-4 1.38(1.14-1.66) p=8E-4 1.02(0.78-1.35) p=0.864
paternal asthma 1568 0.030 1.59(0.86-2.93) p=0.139 2.53(1.30-4.91) p=0.006 1.58(0.86-2.89) p=0.139 0.94(0.38-2.33) p=0.893 1.72(0.83-3.57) p=0.146 0.086 1.88(1.23-2.87) p=0.004 1.43(0.88-2.32) p=0.150 1.24(0.64-2.39) p=0.524
breastfeeding 9198 9E-4 1.42(1.11-1.81) p=0.006 1.53(1.12-2.08) p=0.008 1.22(0.97-1.54) p=0.093 1.04(0.78-1.37) p=0.803 1.04(0.78-1.38) p=0.800 4E-4 1.46(1.20-1.77) p=1E-4 1.31(1.09-1.58) p=0.003 0.96(0.77-1.20) p=0.730
cat 9511 0.179 0.88(0.71-1.09) p=0.226 1.14(0.89-1.45) p=0.291 0.92(0.74-1.13) p=0.427 0.81(0.61-1.06) p=0.125 1.26(0.98-1.62) p=0.073 0.693 0.91(0.78-1.07) p=0.268 0.91(0.78-1.07) p=0.278 1.08(0.88-1.33) p=0.436
FLG 7570 4E-28 4.31(3.29-5.63) p=2E-26 2.23(1.53-3.26) p=3E-5 2.14(1.54-2.98) p=7E-6 1.48(0.92-2.39) p=0.109 2.30(1.57-3.38) p=2E-5 6E-28 3.50(2.81-4.35) p=2E-29 2.03(1.57-2.62) p=7E-8 1.83(1.31-2.55) p=4E-4
genetic risk score 6497 8E-17 1.17(1.12-1.22) p=2E-13 1.08(1.04-1.13) p=4E-4 1.02(0.99-1.06) p=0.222 1.06(1.00-1.12) p=0.042 1.01(0.96-1.06) p=0.758 6E-16 1.14(1.11-1.18) p=2E-19 1.03(1.00-1.06) p=0.033 1.03(0.99-1.07) p=0.153
asthma at age 7 7859 2E-50 5.50(4.28-7.05) p=5E-41 3.08(2.22-4.27) p=2E-11 1.56(1.09-2.24) p=0.015 2.23(1.53-3.26) p=3E-5 1.89(1.26-2.83) p=0.002 2E-49 4.83(3.94-5.91) p=1E-52 1.96(1.52-2.51) p=2E-7 1.76(1.27-2.45) p=8E-4
asthma at age 13 6752 7E-58 7.19(5.48-9.42) p=3E-46 3.59(2.51-5.12) p=2E-12 1.79(1.20-2.65) p=0.004 3.41(2.35-4.96) p=1E-10 2.01(1.30-3.12) p=0.002 9E-59 6.41(5.16-7.97) p=7E-63 2.44(1.87-3.20) p=9E-11 2.23(1.57-3.15) p=6E-6
IgE>75 at age 7 4790 8E-16 2.62(1.98-3.47) p=1E-11 1.92(1.38-2.68) p=1E-4 1.15(0.88-1.51) p=0.310 1.55(1.10-2.18) p=0.013 1.38(0.99-1.93) p=0.059 4E-15 2.59(2.08-3.23) p=2E-17 1.30(1.06-1.61) p=0.012 1.12(0.85-1.47) p=0.417
COMPLETE CASE 6 CLASS COMPLETE CASE 4 CLASS
N omni_p Early-onset persistent Early-onset late-resolving Early-onset  early-resolving Mid-onset resolving Late-onset resolving omni_p Early-onset persistent Early-onset resolving Late-onset resolving
7.9% 8.1% 14.5% 6.0% 8.7% 11.4% 17.1% 11.4%
female 3475 7E-7 1.39(1.05-1.84) p=0.022 1.04(0.77-1.42) p=0.781 0.66(0.49-0.89) p=0.006 1.63(1.10-2.41) p=0.014 2.00(1.41-2.83) p=9E-5 5E-4 1.35(1.07-1.70) p=0.010 0.93(0.74-1.17) p=0.540 1.82(1.37-2.43) p=4E-5
maternal eczema 3473 3E-20 3.35(2.51-4.47) p=2E-16 1.89(1.37-2.58) p=8E-5 2.14(1.60-2.86) p=3E-7 1.97(1.35-2.88) p=5E-4 1.26(0.89-1.78) p=0.194 2E-21 2.86(2.27-3.61) p=1E-18 2.14(1.70-2.69) p=9E-11 1.51(1.13-2.01) p=0.005
maternal asthma 3473 0.006 1.77(1.26-2.49) p=0.001 1.53(1.04-2.25) p=0.031 1.06(0.71-1.58) p=0.781 1.31(0.80-2.14) p=0.282 1.09(0.69-1.71) p=0.713 0.003 1.81(1.37-2.39) p=3E-5 1.26(0.93-1.71) p=0.131 1.17(0.80-1.70) p=0.430
paternal asthma 964 0.042 2.01(0.99-4.06) p=0.052 2.46(1.28-4.76) p=0.007 1.60(0.79-3.25) p=0.193 1.19(0.38-3.73) p=0.767 2.17(0.92-5.14) p=0.077 0.018 2.50(1.49-4.20) p=5E-4 1.58(0.89-2.80) p=0.118 1.94(0.93-4.06) p=0.079
breastfeeding 3435 5E-4 1.13(0.78-1.63) p=0.514 1.91(1.15-3.17) p=0.012 1.75(1.11-2.75) p=0.015 1.45(0.84-2.52) p=0.186 0.64(0.44-0.92) p=0.015 0.008 1.17(0.86-1.59) p=0.327 1.93(1.33-2.82) p=6E-4 0.75(0.54-1.04) p=0.089
cat 3434 0.126 0.87(0.64-1.18) p=0.373 0.89(0.64-1.24) p=0.488 0.64(0.46-0.90) p=0.010 0.76(0.50-1.16) p=0.211 1.00(0.71-1.40) p=0.977 0.116 0.90(0.70-1.15) p=0.408 0.68(0.52-0.88) p=0.004 1.04(0.78-1.40) p=0.773
FLG 2994 6E-11 4.14(2.75-6.22) p=9E-12 2.57(1.55-4.24) p=2E-4 2.60(1.63-4.15) p=7E-5 1.31(0.57-3.02) p=0.521 2.29(1.35-3.89) p=0.002 4E-11 3.48(2.49-4.88) p=4E-13 2.22(1.53-3.23) p=3E-5 1.52(0.91-2.52) p=0.110
genetic risk score 2655 2E-7 1.18(1.11-1.25) p=6E-8 1.05(0.99-1.11) p=0.113 1.03(0.98-1.09) p=0.218 1.08(0.99-1.18) p=0.076 0.96(0.90-1.02) p=0.182 2E-6 1.14(1.09-1.20) p=2E-8 1.05(1.01-1.10) p=0.026 1.00(0.95-1.05) p=0.970
asthma at age 7 3413 2E-25 5.39(3.82-7.61) p=1E-21 3.35(2.23-5.02) p=5E-9 1.24(0.73-2.11) p=0.430 2.16(1.24-3.76) p=0.007 1.15(0.61-2.16) p=0.670 4E-25 5.13(3.83-6.87) p=5E-28 1.95(1.36-2.79) p=3E-4 1.11(0.64-1.93) p=0.704
asthma at age 13 3455 1E-35 6.65(4.73-9.33) p=7E-28 4.24(2.88-6.24) p=2E-13 1.33(0.79-2.25) p=0.289 3.43(2.12-5.55) p=5E-7 1.44(0.81-2.56) p=0.217 3E-37 6.99(5.24-9.33) p=6E-40 2.80(2.00-3.91) p=2E-9 1.54(0.94-2.54) p=0.087
IgE>75 at age 7 2130 1E-8 2.67(1.84-3.87) p=2E-7 2.12(1.42-3.19) p=3E-4 1.11(0.77-1.60) p=0.574 1.68(1.04-2.70) p=0.033 1.19(0.78-1.82) p=0.408 1E-8 2.70(1.98-3.68) p=3E-10 1.61(1.20-2.15) p=0.001 1.02(0.71-1.46) p=0.913
p<0.05 shown in bold
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ACCEPTED MANUSCRIPTTable E10. Association results for 4- and 6- class models in PIAMA
PIAMA 6 CLASS
var N omni_p Early-onset persistent Early-onset late-resolving Early-onset  early-resolving Mid-onset resolving Late-onset resolving
4.9% 3.8% 15.4% 6.5% 6.5%
female 3652 0.025 1.06(0.75-1.49) p=0.743 0.63(0.40-1.00) p=0.051 0.89(0.64-1.24) p=0.494 0.94(0.65-1.37) p=0.753 1.87(1.21-2.90) p=0.005
maternal asthma 3645 0.001 1.94(1.11-3.40) p=0.021 3.14(1.76-5.61) p=1E-4 1.33(0.70-2.51) p=0.385 0.96(0.41-2.24) p=0.932 1.38(0.65-2.93) p=0.406
paternal asthma 3633 0.002 2.69(1.66-4.36) p=6E-5 0.91(0.34-2.46) p=0.854 1.19(0.63-2.25) p=0.585 1.72(0.94-3.14) p=0.076 1.17(0.53-2.61) p=0.697
breastfeeding 3614 0.888 1.00(0.63-1.56) p=0.983 1.34(0.70-2.57) p=0.377 1.19(0.75-1.89) p=0.461 0.97(0.60-1.56) p=0.886 0.88(0.52-1.48) p=0.634
cat 3651 0.151 0.73(0.50-1.06) p=0.098 0.80(0.50-1.29) p=0.367 0.72(0.50-1.04) p=0.081 1.00(0.68-1.47) p=0.996 0.67(0.42-1.07) p=0.094
FLG 1516 6E-4 1.34(0.49-3.67) p=0.563 5.63(2.65-11.95) p=7E-6 0.87(0.25-3.03) p=0.821 0.95(0.26-3.45) p=0.942 1.87(0.76-4.62) p=0.174
genetic risk score 1964 6E-5 1.17(1.07-1.28) p=5E-4 1.00(0.91-1.11) p=0.968 1.16(1.08-1.25) p=1E-4 1.11(1.03-1.20) p=0.004 1.08(0.98-1.18) p=0.111
asthma at age 7 3349 2E-15 14.27(7.33-27.78) p=5E-15 5.92(2.31-15.16) p=2E-4 3.03(1.08-8.47) p=0.035 0.60(0.03-13.62) p=0.750 1.73(0.38-7.88) p=0.478
asthma at age 11 2639 7E-11 15.35(6.86-34.35) p=3E-11 9.12(3.49-23.82) p=6E-6 4.91(1.66-14.55) p=0.004 2.10(0.42-10.53) p=0.366 5.70(1.98-16.43) p=0.001
IgE>75 at age 8 1707 1E-4 3.00(1.85-4.86) p=8E-6 1.58(0.86-2.89) p=0.140 1.57(0.97-2.56) p=0.067 1.42(0.83-2.46) p=0.203 0.97(0.53-1.77) p=0.914
PIAMA 4 CLASS
var omni_p Early-onset persistent Early-onset resolving Late-onset resolving
6.6% 11.4% 10.2%
female 3652 0.004 1.00(0.75-1.34) p=0.984 0.64(0.47-0.87) p=0.004 1.72(1.24-2.39) p=0.001
maternal asthma 3645 0.007 2.07(1.29-3.31) p=0.002 1.91(1.18-3.07) p=0.008 1.51(0.85-2.69) p=0.158
paternal asthma 3633 0.010 2.30(1.51-3.51) p=1E-4 1.12(0.64-1.94) p=0.696 1.05(0.56-1.96) p=0.875
breastfeeding 3614 1.000 1.01(0.68-1.50) p=0.952 1.04(0.70-1.53) p=0.860 0.95(0.63-1.43) p=0.807
cat 3651 0.441 0.86(0.63-1.17) p=0.336 0.75(0.54-1.03) p=0.077 0.87(0.62-1.23) p=0.435
FLG 1516 0.192 1.99(0.97-4.09) p=0.062 2.15(1.04-4.42) p=0.038 1.36(0.60-3.12) p=0.464
genetic risk score 1964 0.005 1.13(1.05-1.21) p=0.001 1.08(1.01-1.15) p=0.019 1.05(0.98-1.12) p=0.173
asthma at age 7 3349 1E-12 8.77(5.13-14.97) p=2E-15 3.45(1.70-7.00) p=6E-4 0.46(0.03-7.05) p=0.579
asthma at age 11 2639 3E-10 8.43(4.61-15.42) p=4E-12 5.47(2.76-10.85) p=1E-6 2.80(1.12-7.03) p=0.028
IgE>75 at age 8 1707 3E-6 2.64(1.74-4.00) p=5E-6 2.30(1.49-3.55) p=2E-4 1.04(0.66-1.65) p=0.854
p<0.05 shown in bold
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Table E11. Association results for individual SNPs with 4- and 6- class models in ALSPAC & PIAMA
ALSPAC 6 CLASS PIAMA 6 CLASS
var Chr Nearest gene omni_p Early-onset persistent Early-onset late-resolving Early-onset  early-resolving Mid-onset resolving Late-onset resolving var Chr Nearest gene omni_p Early-onset persistent Early-onset late-resolving Early-onset  early-resolving Mid-onset resolving Late-onset resolving
7.3% 7.0% 12.9% 7.0% 7.9% 4.9% 3.8% 15.4% 6.5% 6.5%
rs10214237_t 5 IL7R 0.852 1.01(0.83-1.22) p=0.960 1.09(0.87-1.37) p=0.434 1.00(0.82-1.21) p=0.984 1.08(0.86-1.37) p=0.496 1.11(0.88-1.39) p=0.379 rs10214237_t 5 IL7R 0.486 1.07(0.74-1.55) p=0.724 0.78(0.53-1.15) p=0.211 0.96(0.67-1.40) p=0.845 1.22(0.85-1.75) p=0.274 1.25(0.83-1.88) p=0.279
rs1057258_c 2 INPP5D 0.011 1.19(0.93-1.52) p=0.162 0.87(0.68-1.11) p=0.256 0.80(0.65-0.99) p=0.039 0.92(0.70-1.22) p=0.577 0.73(0.57-0.93) p=0.011 rs1057258_c 2 INPP5D 0.405 0.83(0.53-1.28) p=0.391 0.77(0.50-1.18) p=0.234 1.00(0.65-1.53) p=1.000 0.78(0.52-1.18) p=0.243 0.74(0.45-1.20) p=0.218
rs10995251_c 10 ZNF365 0.711 0.96(0.82-1.14) p=0.664 1.19(0.96-1.47) p=0.107 0.95(0.81-1.12) p=0.571 1.01(0.81-1.26) p=0.908 0.99(0.81-1.20) p=0.896 rs10995251_c 10 ZNF365 0.480 1.22(0.85-1.76) p=0.280 0.94(0.62-1.42) p=0.779 1.35(0.95-1.93) p=0.096 0.98(0.68-1.40) p=0.913 0.83(0.53-1.29) p=0.401
rs112111458_a 2 CD207 0.581 0.97(0.77-1.22) p=0.799 1.31(0.95-1.81) p=0.096 0.95(0.75-1.20) p=0.681 0.89(0.67-1.17) p=0.387 0.94(0.71-1.24) p=0.665 rs112111458_a 2 CD207 0.454 1.42(0.83-2.42) p=0.202 0.68(0.41-1.15) p=0.155 0.99(0.59-1.68) p=0.979 1.36(0.72-2.57) p=0.342 0.85(0.51-1.45) p=0.558
rs11657987_t 17 PGS1 0.613 1.11(0.94-1.33) p=0.225 1.08(0.88-1.32) p=0.461 1.04(0.89-1.23) p=0.596 1.10(0.88-1.37) p=0.396 1.03(0.86-1.24) p=0.742 rs11657987_t 17 PGS1 0.421 1.11(0.82-1.48) p=0.505 0.71(0.50-1.02) p=0.065 1.14(0.82-1.58) p=0.433 1.13(0.82-1.56) p=0.450 1.04(0.72-1.49) p=0.851
rs12153855_t 6 TNXB 0.059 1.35(1.01-1.80) p=0.043 1.16(0.84-1.61) p=0.369 1.02(0.77-1.33) p=0.908 1.55(1.02-2.36) p=0.040 1.13(0.81-1.57) p=0.468 rs12153855_t 6 TNXB 0.742 1.34(0.67-2.69) p=0.405 1.15(0.52-2.57) p=0.733 1.35(0.74-2.46) p=0.333 1.20(0.61-2.38) p=0.596 1.60(0.59-4.34) p=0.359
rs12295535_t 11 PRR5L 0.026 1.54(1.02-2.34) p=0.040 1.55(0.94-2.54) p=0.086 1.19(0.74-1.93) p=0.468 1.19(0.68-2.06) p=0.543 0.39(0.13-1.17) p=0.094 rs12295535_t 11 PRR5L 0.694 0.25(0.03-2.40) p=0.228 1.37(0.50-3.74) p=0.544 1.15(0.44-3.01) p=0.779 1.50(0.66-3.43) p=0.337 1.44(0.53-3.88) p=0.471
rs16948048_g 17 ZNF652 0.214 0.97(0.82-1.15) p=0.762 1.21(1.00-1.47) p=0.046 0.93(0.79-1.10) p=0.404 0.91(0.73-1.12) p=0.355 0.88(0.71-1.10) p=0.263 rs16948048_g 17 ZNF652 0.071 1.17(0.84-1.62) p=0.350 1.17(0.76-1.79) p=0.482 0.95(0.68-1.31) p=0.746 1.58(1.15-2.16) p=0.005 0.96(0.65-1.42) p=0.834
rs17389644_a 4 IL21 0.602 1.07(0.88-1.32) p=0.495 1.18(0.94-1.49) p=0.153 1.08(0.89-1.32) p=0.444 1.03(0.80-1.33) p=0.794 1.00(0.78-1.29) p=0.981 rs17389644_a 4 IL21 0.141 1.43(0.98-2.08) p=0.062 1.44(0.93-2.23) p=0.098 0.91(0.63-1.30) p=0.595 1.16(0.73-1.85) p=0.537 1.04(0.61-1.77) p=0.895
rs17881320_t 17 STAT3 0.002 1.67(1.28-2.18) p=1E-4 0.95(0.62-1.44) p=0.801 1.02(0.74-1.39) p=0.905 1.39(0.97-2.00) p=0.076 1.05(0.73-1.50) p=0.792 rs17881320_t 17 STAT3 0.078 1.81(1.08-3.06) p=0.026 1.04(0.44-2.47) p=0.933 1.92(1.16-3.16) p=0.011 1.27(0.69-2.35) p=0.448 0.75(0.27-2.09) p=0.584
rs2041733_t 16 CLEC16A 0.558 1.03(0.88-1.22) p=0.703 1.03(0.85-1.25) p=0.785 1.06(0.90-1.26) p=0.493 1.19(0.97-1.46) p=0.099 0.92(0.75-1.13) p=0.426 rs2041733_t 16 CLEC16A 0.094 1.38(0.98-1.94) p=0.065 0.96(0.66-1.38) p=0.809 1.15(0.83-1.59) p=0.390 1.46(1.07-2.01) p=0.018 1.15(0.78-1.69) p=0.490
rs2143950_t 14 PPP2R3C 0.003 1.32(1.07-1.62) p=0.008 1.23(0.96-1.57) p=0.099 0.86(0.67-1.10) p=0.219 1.28(0.99-1.65) p=0.063 1.13(0.88-1.45) p=0.344 rs2143950_t 14 PPP2R3C 0.297 1.37(0.92-2.02) p=0.118 0.99(0.58-1.68) p=0.956 1.20(0.80-1.81) p=0.384 0.63(0.36-1.09) p=0.098 0.90(0.52-1.58) p=0.721
rs2164983_a 19 ACTL9 6E-5 1.55(1.28-1.89) p=1E-5 1.18(0.90-1.54) p=0.228 1.27(1.01-1.58) p=0.037 1.29(0.98-1.69) p=0.067 1.02(0.75-1.40) p=0.901 rs2164983_a 19 ACTL9 0.100 1.30(0.83-2.03) p=0.247 1.49(0.92-2.40) p=0.102 0.76(0.47-1.22) p=0.255 0.92(0.56-1.51) p=0.739 1.55(0.96-2.50) p=0.074
rs2227483_t 12 IL22 0.593 1.12(0.94-1.33) p=0.207 0.88(0.71-1.08) p=0.217 1.03(0.87-1.22) p=0.698 1.07(0.86-1.32) p=0.555 1.10(0.90-1.35) p=0.361 rs2227483_t 12 IL22 0.008 1.36(1.01-1.82) p=0.043 0.93(0.62-1.40) p=0.735 1.63(1.15-2.31) p=0.006 1.00(0.70-1.44) p=0.996 1.89(1.19-2.99) p=0.007
rs2228145_c 1 IL6R 0.002 1.36(1.15-1.60) p=4E-4 1.07(0.88-1.30) p=0.520 0.95(0.80-1.14) p=0.594 1.05(0.85-1.28) p=0.658 0.87(0.71-1.07) p=0.193 rs2228145_c 1 IL6R 0.368 0.97(0.70-1.34) p=0.833 1.27(0.89-1.82) p=0.184 1.30(0.96-1.77) p=0.094 0.88(0.63-1.24) p=0.480 1.14(0.80-1.64) p=0.473
rs2897442_c 5 KIF3A 0.007 1.35(1.13-1.62) p=9E-4 0.91(0.72-1.15) p=0.443 0.95(0.78-1.16) p=0.621 1.18(0.95-1.47) p=0.131 0.88(0.70-1.11) p=0.286 rs2897442_c 5 KIF3A 0.542 1.04(0.71-1.52) p=0.832 1.23(0.81-1.85) p=0.327 0.73(0.47-1.14) p=0.167 1.03(0.70-1.51) p=0.894 1.19(0.80-1.77) p=0.394
rs479844_g 11 OVOL1 0.002 1.29(1.08-1.53) p=0.004 1.30(1.07-1.59) p=0.008 1.07(0.90-1.28) p=0.419 0.98(0.76-1.24) p=0.840 1.10(0.90-1.33) p=0.363 rs479844_g 11 OVOL1 0.341 1.47(1.02-2.10) p=0.038 0.99(0.68-1.45) p=0.971 1.08(0.78-1.49) p=0.643 1.15(0.82-1.60) p=0.417 0.86(0.58-1.28) p=0.451
rs6010620_g 20 RTEL1 0.174 1.24(1.01-1.51) p=0.038 1.18(0.92-1.51) p=0.200 1.07(0.89-1.29) p=0.468 1.02(0.81-1.29) p=0.840 1.04(0.83-1.31) p=0.721 rs6010620_g 20 RTEL1 0.359 1.63(1.06-2.52) p=0.027 0.94(0.61-1.44) p=0.768 1.20(0.86-1.68) p=0.287 1.00(0.69-1.45) p=0.992 1.00(0.65-1.54) p=0.986
rs6473227_c 8 ZBTB10 0.208 1.10(0.93-1.30) p=0.259 1.10(0.90-1.35) p=0.361 1.13(0.95-1.34) p=0.159 1.18(0.95-1.46) p=0.142 1.12(0.91-1.37) p=0.299 *
rs6602364_g 10 IL2RA 0.935 0.95(0.81-1.12) p=0.552 1.02(0.83-1.26) p=0.834 0.99(0.83-1.18) p=0.928 0.89(0.71-1.13) p=0.351 0.98(0.79-1.21) p=0.854 rs6602364_g 10 IL2RA 0.033 0.98(0.71-1.34) p=0.892 0.71(0.45-1.12) p=0.143 1.22(0.86-1.72) p=0.261 1.03(0.71-1.49) p=0.891 1.60(1.17-2.20) p=0.003
rs7127307_t 11 ETS1 0.465 1.16(0.98-1.37) p=0.078 0.97(0.81-1.17) p=0.752 1.04(0.88-1.22) p=0.673 1.02(0.84-1.23) p=0.864 1.15(0.94-1.40) p=0.165 rs7127307_t 11 ETS1 0.542 1.05(0.77-1.44) p=0.761 1.07(0.70-1.63) p=0.769 1.29(0.95-1.74) p=0.098 1.07(0.77-1.47) p=0.698 0.81(0.53-1.24) p=0.340
rs7146581_c 14 TRAF3 0.215 1.22(0.99-1.50) p=0.068 1.04(0.82-1.31) p=0.758 1.22(0.99-1.50) p=0.064 1.06(0.83-1.34) p=0.655 1.14(0.90-1.44) p=0.282 rs7146581_c 14 TRAF3 0.421 0.86(0.60-1.25) p=0.437 1.08(0.67-1.74) p=0.744 1.40(0.95-2.07) p=0.087 1.14(0.73-1.80) p=0.561 1.18(0.73-1.92) p=0.503
rs7927894_t 11 C11orf30 0.023 1.27(1.08-1.50) p=0.005 1.00(0.82-1.22) p=0.976 0.91(0.77-1.07) p=0.253 1.10(0.89-1.35) p=0.370 1.13(0.92-1.38) p=0.232 rs7927894_t 11 C11orf30 0.608 0.98(0.70-1.38) p=0.913 0.99(0.67-1.48) p=0.977 1.05(0.76-1.44) p=0.767 1.40(0.99-1.99) p=0.061 0.99(0.64-1.53) p=0.971
ALSPAC 4 CLASS PIAMA 4 CLASS
var Chr Nearest gene omni_p Early-onset persistent Early-onset resolving Late-onset resolving var Chr Nearest gene omni_p Early-onset persistent Early-onset resolving Late-onset resolving
10.7% 16.5% 10.9% 6.6% 11.4% 10.2%
rs10214237_t 5 IL7R 0.983 1.03(0.89-1.19) p=0.695 0.98(0.84-1.13) p=0.749 1.07(0.89-1.27) p=0.489 rs10214237_t 5 IL7R 0.985 1.08(0.79-1.47) p=0.635 0.97(0.71-1.32) p=0.845 1.10(0.82-1.48) p=0.515
rs1057258_c 2 INPP5D 0.123 1.10(0.92-1.31) p=0.301 0.87(0.74-1.02) p=0.083 0.81(0.66-0.99) p=0.042 rs1057258_c 2 INPP5D 0.369 0.79(0.56-1.13) p=0.194 1.12(0.79-1.60) p=0.529 0.72(0.50-1.02) p=0.066
rs10995251_c 10 ZNF365 0.883 1.00(0.88-1.13) p=0.975 1.09(0.96-1.24) p=0.199 0.98(0.83-1.15) p=0.800 rs10995251_c 10 ZNF365 0.876 1.18(0.88-1.59) p=0.278 1.03(0.75-1.42) p=0.853 0.89(0.66-1.20) p=0.443
rs112111458_a 2 CD207 0.246 1.00(0.83-1.20) p=0.991 1.21(0.99-1.47) p=0.057 0.83(0.67-1.03) p=0.087 rs112111458_a 2 CD207 0.844 1.18(0.76-1.84) p=0.457 0.83(0.57-1.21) p=0.343 1.19(0.75-1.87) p=0.466
rs11657987_t 17 PGS1 0.382 1.12(0.98-1.27) p=0.099 1.11(0.98-1.26) p=0.100 1.03(0.88-1.21) p=0.693 rs11657987_t 17 PGS1 0.803 1.03(0.80-1.33) p=0.800 0.83(0.64-1.07) p=0.153 1.06(0.81-1.40) p=0.658
rs12153855_t 6 TNXB 0.056 1.33(1.06-1.66) p=0.012 1.16(0.93-1.44) p=0.191 1.33(0.99-1.77) p=0.055 rs12153855_t 6 TNXB 0.882 1.32(0.73-2.40) p=0.354 1.23(0.70-2.14) p=0.473 1.19(0.64-2.19) p=0.581
rs12295535_t 11 PRR5L 0.129 1.44(1.04-2.00) p=0.027 1.24(0.88-1.76) p=0.216 0.64(0.34-1.18) p=0.151 rs12295535_t 11 PRR5L 0.557 0.27(0.04-1.69) p=0.163 1.63(0.85-3.14) p=0.144 1.09(0.48-2.51) p=0.836
rs16948048_g 17 ZNF652 0.682 0.99(0.88-1.13) p=0.925 1.01(0.89-1.15) p=0.890 0.86(0.72-1.02) p=0.080 rs16948048_g 17 ZNF652 0.143 1.05(0.79-1.41) p=0.725 1.40(1.06-1.84) p=0.016 1.25(0.94-1.66) p=0.124
rs17389644_a 4 IL21 0.544 1.11(0.96-1.30) p=0.170 1.13(0.97-1.31) p=0.124 1.01(0.83-1.22) p=0.959 rs17389644_a 4 IL21 0.031 1.72(1.26-2.34) p=6E-4 1.14(0.83-1.57) p=0.408 1.03(0.69-1.52) p=0.897
rs17881320_t 17 STAT3 0.062 1.40(1.13-1.74) p=0.002 1.15(0.91-1.44) p=0.238 1.12(0.84-1.51) p=0.432 rs17881320_t 17 STAT3 0.133 1.62(1.01-2.58) p=0.044 1.62(1.06-2.47) p=0.026 1.10(0.62-1.94) p=0.745
rs2041733_t 16 CLEC16A 0.912 1.06(0.94-1.21) p=0.333 1.01(0.89-1.15) p=0.904 1.07(0.91-1.26) p=0.394 rs2041733_t 16 CLEC16A 0.223 1.37(1.03-1.81) p=0.030 1.03(0.79-1.36) p=0.818 1.26(0.95-1.67) p=0.114
rs2143950_t 14 PPP2R3C 0.014 1.34(1.15-1.56) p=2E-4 1.01(0.85-1.20) p=0.892 1.13(0.92-1.39) p=0.262 rs2143950_t 14 PPP2R3C 0.517 1.31(0.93-1.86) p=0.124 0.97(0.67-1.41) p=0.878 0.75(0.48-1.15) p=0.189
rs2164983_a 19 ACTL9 4E-4 1.42(1.21-1.66) p=2E-5 1.21(1.01-1.43) p=0.034 1.19(0.96-1.49) p=0.112 rs2164983_a 19 ACTL9 0.311 1.27(0.86-1.87) p=0.229 0.94(0.63-1.38) p=0.735 1.49(1.03-2.17) p=0.036
rs2227483_t 12 IL22 0.604 1.05(0.92-1.20) p=0.483 0.98(0.87-1.11) p=0.767 1.16(0.99-1.38) p=0.074 rs2227483_t 12 IL22 0.633 1.19(0.92-1.53) p=0.186 1.01(0.77-1.34) p=0.928 1.25(0.90-1.72) p=0.180
rs2228145_c 1 IL6R 5E-4 1.32(1.16-1.50) p=2E-5 0.96(0.84-1.09) p=0.502 0.90(0.77-1.06) p=0.192 rs2228145_c 1 IL6R 0.967 0.96(0.73-1.25) p=0.759 1.12(0.86-1.45) p=0.396 1.04(0.79-1.36) p=0.785
rs2897442_c 5 KIF3A 0.126 1.22(1.06-1.40) p=0.005 0.96(0.83-1.12) p=0.622 0.99(0.82-1.18) p=0.872 rs2897442_c 5 KIF3A 0.798 1.17(0.85-1.61) p=0.332 1.00(0.72-1.39) p=0.995 1.21(0.90-1.64) p=0.215
rs479844_g 11 OVOL1 0.002 1.34(1.17-1.53) p=2E-5 1.06(0.92-1.21) p=0.434 1.06(0.90-1.24) p=0.510 rs479844_g 11 OVOL1 0.457 1.38(1.01-1.89) p=0.042 1.05(0.80-1.38) p=0.710 0.92(0.70-1.20) p=0.524
rs6010620_g 20 RTEL1 0.057 1.24(1.06-1.45) p=0.006 0.94(0.81-1.08) p=0.381 1.17(0.97-1.42) p=0.094 rs6010620_g 20 RTEL1 0.958 1.13(0.81-1.56) p=0.470 1.08(0.80-1.46) p=0.619 1.10(0.78-1.53) p=0.591
rs6473227_c 8 ZBTB10 0.113 1.09(0.96-1.25) p=0.179 1.16(1.02-1.31) p=0.026 1.16(0.98-1.37) p=0.087 *
rs6602364_g 10 IL2RA 0.928 0.98(0.86-1.11) p=0.708 0.97(0.85-1.12) p=0.706 0.91(0.77-1.08) p=0.291 rs6602364_g 10 IL2RA 0.894 0.86(0.65-1.14) p=0.291 1.11(0.83-1.48) p=0.486 1.00(0.76-1.32) p=1.000
rs7127307_t 11 ETS1 0.583 1.08(0.95-1.22) p=0.235 0.97(0.85-1.10) p=0.601 1.13(0.96-1.32) p=0.130 rs7127307_t 11 ETS1 0.723 1.10(0.83-1.46) p=0.521 1.09(0.84-1.41) p=0.533 0.80(0.60-1.08) p=0.149
rs7146581_c 14 TRAF3 0.364 1.17(1.00-1.38) p=0.048 1.10(0.94-1.28) p=0.244 1.07(0.89-1.30) p=0.453 rs7146581_c 14 TRAF3 0.627 0.86(0.62-1.18) p=0.344 1.30(0.92-1.84) p=0.131 1.06(0.74-1.51) p=0.764
rs7927894_t 11 C11orf30 0.132 1.19(1.05-1.35) p=0.007 0.98(0.87-1.12) p=0.806 1.11(0.94-1.31) p=0.216 rs7927894_t 11 C11orf30 0.995 1.04(0.77-1.41) p=0.779 1.07(0.81-1.42) p=0.615 1.04(0.77-1.41) p=0.779
Each risk allele is shown after the rs number; p<0.05 shown in bold
* rs6473227 was unavailable in PIAMA
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